Patients with Alzheimer’s disease – the most common cause of dementia – may soon get a new drug that can slow progression of the disease, a recent study has found.
Speaking to media on Tuesday, visiting consultant in the Department of Psychological Medicine at the National University Hospital (NUH) Christopher Chen (Associate Professor at Department of Pharmacology, NUS) said disease progression for patients who were given the drug known as lecanemab was found to be at least six months behind those who received a placebo after 18 months of treatment.